

**Table 1** Characteristics of the 239 patients enrolled in the study

	<b>ARST0531 Total=85 N (%)</b>	<b>RMS2005 Total=154 N (%)</b>	<b>P-value<sup>1</sup></b>
<b>Sex</b>			1.0
Female	38 (44)	68 (44)	
Male	47 (56)	86 (56)	
<b>Age at diagnosis (years)</b>			0.14
0-1	5 (6)	3 (2)	
1-10	34 (40)	77 (50)	
10+	46 (54)	74 (48)	
<b>Tumor size</b>			0.0029
≤5 cm	40 (47)	42 (27)	
>5 cm	45 (53)	110 (71)	
Unknown	0	2 (2)	
<b>Histology</b>			0.14
Alveolar RMS	75 (96)	145 (94)	
Mixed	3 (4)	3 (2)	
Embryonal/Alveolar			
Solid Alveolar RMS	0	6 (4)	
<b>Clinical nodal status</b>			0.21
Negative	4 (5)	15 (10)	
Positive	81 (95)	139 (90)	
<b>Pathologic nodal status*</b>			0.0035
Negative	18 (21)	6 (4)	
Positive	51 (60)	71 (46)	
<b>IRS Group</b>			0.0090 (0.0027) <sup>2</sup>
I	1	0	
Ila	1	0	
Ilb	6 (7)	5 (3.5)	
Ilc	9 (10)	5 (3.5)	
III	68 (80)	144 (93)	
<b>T-stage</b>			0.58
T-1	30 (35)	61 (40)	
T-2	55 (65)	92 (60)	
Unknown	0	1	

**FOXO1 fusion status**

Negative	17 (20)	30 (19)
PAX3+	41 (48)	55 (36)
PAX7 +	8 (9)	11 (7)
FOXO1 +	13 (15)	28 (18)
Unknown	6 (7)	30 (19)

0.64  
(0.73)<sup>3</sup>

**Primary site**

Orbit	0	1
Head neck non-PM	11 (13)	27 (17)
Parameningeal (PM)	29 (34)	39 (25)
Bladder-Prostate (BP)	2 (2)	5 (3)
Genito-Urinary non-BP	2 (2)	4 (2)
Extremities	27 (32)	54 (35)
Other sites	14 (16)	24 (15)

0.83

\* Pathologic confirmation not mandatory; <sup>1</sup>Fisher's exact test;

<sup>2</sup> Comparing Group I, II (IIa+IIb+IIc) and III (Definition of Groups and T-stage: Suppl. Table S1);

<sup>3</sup> Comparing FOXO1- and FOXO1+ (PAX3+PAX7+FOXO1)